Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Neuropsychopharmacol Rep ; 41(2): 179-184, 2021 06.
Article En | MEDLINE | ID: mdl-33606356

AIM: As an emergency measure during the coronavirus disease pandemic, the monitoring interval for clozapine use was temporarily extended beyond the regulatory requirement in Japan, which is the safest monitoring interval worldwide. In this study, we aimed to explore the effect of this measure on patients undergoing clozapine treatment. METHODS: This retrospective chart review study included patients with treatment-resistant schizophrenia (TRS) who were undergoing clozapine treatment at four psychiatric institutions in Japan. Demographic characteristics and clinical information of these patients were collected on April 27, 2020, when Japanese psychiatrists were virtually allowed to prescribe clozapine beyond the regulatory requirement. Furthermore, information of adverse events related to the emergency measure was collected and analyzed. RESULTS: Of the 41 patients with TRS included in this study, 19 patients underwent extended hematological monitoring during clozapine treatment. No psychiatric or hematological adverse events were observed in the patients during the extended monitoring interval. CONCLUSION: This study suggested that there were few adverse events of clozapine-treated patients related to emergency measures in Japan. However, hematological monitoring intervals during clozapine treatment have been emergently extended worldwide; hence, it is necessary to verify the results of these measures.


Agranulocytosis/epidemiology , Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Schizophrenia/drug therapy , Adult , Agranulocytosis/chemically induced , COVID-19 , Drug Monitoring/standards , Female , Humans , Japan/epidemiology , Male , Retrospective Studies , SARS-CoV-2
2.
Neuropsychopharmacol Rep ; 40(4): 332-341, 2020 12.
Article En | MEDLINE | ID: mdl-32896111

AIM: The objective of the current study was to identify risk factors that affect the onset of dependence and chronic psychosis due to cannabis use. METHODS: We examined clinical genetic factors, psychiatric disorders prior to cannabis use, starting age of cannabis use, duration and frequency of cannabis use, types of cannabis products used, combined use of other psychoactive substances, and the psychiatric diagnosis of 71 patients with cannabis-related psychiatric disorders who underwent treatment at nine mental health hospitals in Japan. Information was collected from cross-sectional interview surveys conducted by each patient's attending psychiatrist. RESULTS: For the diagnosis of dependence syndrome due to the use of cannabis, we found associations with the number of years of cannabis use and the use of cannabis products with a high Δ9-tetrahydrocannabinol (THC) content. However, we found no association between diagnosis of residual and late-onset psychotic disorders and clinical genetic factors, presence of preceding psychiatric disorders, duration and frequency of cannabis use, starting age of cannabis use, or combined use of other psychoactive substances; an association was found only for the absence of use of cannabis products other than dried cannabis. CONCLUSION: The onset of cannabis dependence was related to long-term cannabis use and the use of cannabis products with a high THC content. However, chronic psychosis was not associated with total THC intake or psychiatric vulnerability. Thus, unknown factors appear to be involved in the onset of chronic psychosis.


Marijuana Abuse/epidemiology , Marijuana Abuse/psychology , Psychotic Disorders/epidemiology , Psychotic Disorders/psychology , Surveys and Questionnaires , Adult , Age Factors , Chronic Disease , Female , Humans , Japan/epidemiology , Male , Marijuana Abuse/complications , Middle Aged , Psychotic Disorders/etiology , Risk Factors
3.
J Med Invest ; 55(1-2): 156-60, 2008 Feb.
Article En | MEDLINE | ID: mdl-18319560

Numbers of individuals infected with Human Immunodeficiency Virus (HIV) are increasing in Japan. The majority of them are Men who have sex with men and a part of them take drugs as 'Sex drug' at their sexual intercourse. Especially, Amyl nitrite, Methamphetamine, 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT; Foxy), and 3, 4-methylenedioxy- methamphetamine (MDMA; Ecstasy) are used, and they sometimes cause the physical and mental disorders. However, the actual drug inducing troubles among Japanese HIV-infected drug users had not yet been discussed enough. In this report, we describe three cases with HIV infection; a case developed severe neuroleptic malignant syndrome (NMS) after taking 5-MeO-DIPT, a case with persistent convulsion due to multiple drug intake and a case with rhabdomyolysis due to the non-subjective methamphetamine intake. Through these cases, we raise and discuss several underlying problems associated with drug use among HIV-infected individuals.


HIV Infections/complications , Neuroleptic Malignant Syndrome/etiology , Rhabdomyolysis/etiology , Seizures/etiology , Substance-Related Disorders/complications , 5-Methoxytryptamine/adverse effects , 5-Methoxytryptamine/analogs & derivatives , Adult , Amyl Nitrite/adverse effects , Antiretroviral Therapy, Highly Active , Asian People , Drug Interactions , HIV Infections/drug therapy , Humans , Male , Methamphetamine/adverse effects , N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
4.
Genes Genet Syst ; 77(1): 59-62, 2002 Feb.
Article En | MEDLINE | ID: mdl-12036105

Sensitivity to the bitter taste of chloramphenicol was studied in 860 students, 620 males and 240 females. About 8.6% of them were insensitive to this bitter taste. Familial lineage studies were carried out on a subset of these students, and the results suggested that the sensitivity or insensitivity was controlled by a pair of autosomal Mendelian genes, with the sensitive gene being dominant over the insensitive.


Chloramphenicol , Genes, Recessive , Taste/genetics , Adolescent , Adult , Chloramphenicol/administration & dosage , Female , Humans , Male , Pedigree , Phenylthiourea/administration & dosage
...